- Home
- CDTX
as 11-15-2024 4:00pm EST
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 79.3M | IPO Year: | 2015 |
| Target Price: | $30.50 | AVG Volume (30 days): | 21.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.00 - $24.40 | Next Earning Date: | 11-07-2024 |
| Revenue: | $44,653,000 | Revenue Growth: | 19.60% |
| Revenue Growth (this year): | -84.04% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cidara Therapeutics Inc. (CDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandison Taylor | CDTX | Chief Medical Officer | Sep 11 '24 | Sell | $11.64 | 924 | $10,752.31 | 23,067 | |
| Tari Leslie | CDTX | CHIEF SCIENTIFIC OFFICER | Sep 11 '24 | Sell | $11.64 | 909 | $10,580.12 | 17,788 |
Latest Cidara Therapeutics Inc. News
CDTX Breaking Stock News: Dive into CDTX Ticker-Specific Updates for Smart Investing
Associated Press Finance
10 days ago
Cidara Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
17 days ago
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
GlobeNewswire
a month ago
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024
GlobeNewswire
a month ago
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire
2 months ago
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
GlobeNewswire
2 months ago
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
GlobeNewswire
2 months ago
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
Pharmaceutical Technology
2 months ago
Cidara axes 30% of staff to focus on flu prevention drug
Compare CDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDTX Cidara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.